OUTLOOK AND PLANS INOVIQ is focused on its vison to be a leading exosome and precision diagnostics company delivering next-generation products to improve patient health outcomes and help save lives. The Company’s key commercial objectives to drive shareholder value over the next 12-months are to advance its lead SubB2M diagnostics towards commercialisation, expand its EXO-NET exosome isolation tools, accelerate development of its exosome diagnostic pipeline, and generate revenues through product sales and partnering of its exosome technologies. The Company expects to report key data readouts for its SubB2M and exosome diagnostic programs, as well as commercial progress, and looks forward to updating shareholders on these milestones and catalysts over the next 12 months. The Company is strongly positioned with differentiated technology, a multi-product pipeline, growing partnering interest and an experienced team to execute on strategy, deliver key development / commercial milestones, and grow shareholder value over the next 12 months. H2 CY 2023 H1 CY 2024 • EXO-NET co-marketing agreement with Promega • Results of EXO-OC equivalence study in plasma and serum (n=250) • Results SubB2M SPR feasibility study • Results SubB2M/CA125 OC analytical valdation study • Results of SubB2M/CA15-3 BC monitoring study • Progress SubB2M partnering • TEXO-NET data @ ANZSEV23 meeting • Commercial progress SubB2M/CA15-3 test • Results SubB2M/CA125 clinical validation studies • NEURO-NET data • New EXO-NET collaborations/partnering • Progress EXO-OC clinical study 19 Annual Report 2023
RkJQdWJsaXNoZXIy MjE2NDg3